SCHEMBL8081279

SCHEMBL8081279

Cc1cc2c(cc1N)C(=O)CO2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
IMPDH2 P12268 1/20 0.36
IMPDH1 P20839 1/20 0.36
MAPT P10636 6/20 0.36
HSD17B10 Q99714 4/20 0.36
KDM4E B2RXH2 2/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
ATAD2 Q6PL18 1/20 0.35
MAOA P21397 3/20 0.35
MAOB P27338 3/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
ALDH1A1 P00352 3/20 0.33
CYP2C9 P11712 2/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31358695 0.84 IMPDH2 (0.47) IMPDH2IMPDH1MAPTHSD17B10KDM4E
SCHEMBL19627183 0.84 IMPDH2 (0.47) IMPDH2IMPDH1MAPTHSD17B10KDM4E
SCHEMBL30601566 0.81 MAPT (0.37) IMPDH2IMPDH1MAPTHSD17B10KDM4E
SCHEMBL22438910 0.81 MAPT (0.37) IMPDH2IMPDH1MAPTHSD17B10KDM4E
SCHEMBL17785121 0.75 KDM4E (0.50) CYP3A4MAPK1MAPTHSD17B10KDM4E
SCHEMBL12316639 0.75 MAOB (0.47) MAPTHSD17B10KDM4EATAD2MAOA
SCHEMBL1430018 0.74 PSMB5 (0.41) CYP3A4MAPK1IMPDH2IMPDH1MAPT
SCHEMBL19627161 0.74 HSD17B10 (0.39) IMPDH2IMPDH1MAPTHSD17B10KDM4E
SCHEMBL8083405 0.73 POLB (0.39) CYP3A4TSHRMAPTMAOAMEN1
SCHEMBL16357239 0.72 MAPT (0.42) MAPK1MAPTHSD17B10KDM4ECASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009155042-A1 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-12-23 WO disclosed
US-20090311217-A1 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-12-17 US disclosed
US-20090311217-A1 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090311217-A1 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES MTOR, RICTOR, PDPK1 CYP3A4 1181/4885TSHR 3312/4885MAPK1 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.